Sanofi signed a deal with Earendil Labs for $125 million upfront and $1.72 billion in milestone payments. Regeneron ... Health and Human Services issued a Stop Work Order for GeoVax’s investigational ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

Sanofi SNY and partner Regeneron REGN announced that the FDA approved Dupixent (dupilumab) for the treatment of chronic ...

EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion ...

Up to five-year contract extension to support the WFH Humanitarian Aid Program with medicine donations and financial ...

This is a study that could potentially change the standard of care," Berger said ... Future of Healthcategory Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition April 18, 2025 Future ...

All patients were treated with standard-of-care therapy, including medium-to-high doses of ... with COPD is expected to launch later this year. In collaboration with Regeneron, Sanofi announced the ...

Paris: Sanofi and Regeneron Pharma have received approval from the US Food ... Dupixent is intended for use under the guidance of a healthcare professional and can be given in a clinic or at home ...

TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the ... inadequately controlled disease on standard-of-care ...

We look forward to bringing Dupixent to the more than 300,000 CSU patients in the US with inadequately controlled disease on standard-of-care treatment who ... Dupilumab is being jointly developed by ...

The U.S. Food and Drug Administration approved the use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with ...